Acute cellular rejection the first year after heart transplantation and its impact on survival: A single-centre retrospective study at Skåne University Hospital in Lund 1988-2010

Transplant International

Volumn 27, Issue 5, 2014, Pages 482-492

  Söderlund, Carl ^a,b   Öhman, Jenny ^a   Nilsson, Johan ^b   Higgins, Thomas ^b   Kornhall, Björn ^b   Johansson, Leif ^b   Rådegran, Göran ^b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

acute rejection; cardiac transplantation; first year

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CHILD; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DONOR; FEMALE; GRAFT FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NEOPLASM; PRIORITY JOURNAL; RECIPIENT; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; ACUTE DISEASE; AGED; BIOPSY; CAUSE OF DEATH; GRAFT REJECTION; HEART MUSCLE; MIDDLE AGED; PATHOLOGY; TIME;

ACUTE DISEASE; ADULT; AGED; BIOPSY; CAUSE OF DEATH; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIUM; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84898793574     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12284     Document Type: Article

References (39)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al,. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report-2011. J Heart Lung Transplant 2011; 10: 1078.
2. Sakakibara S, Konno S,. Endomyocardial biopsy. Jpn Heart J 1962; 3: 537.
3. Caves PK, Stinson EB, Billingham M, Shumway NE,. Percutaneous transvenous endomyocardial biopsy in human heart recipients. Experience with a new technique. Ann Thorac Surg 1973; 16: 325.
4. Zerbe TR, Arena V,. Diagnostic reliability of endomyocardial biopsy for assessment of cardiac allograft rejection. Hum Pathol 1988; 19: 1307.
5. Billingham ME, Cary NR, Hammond ME, et al,. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587.
6. Stewart S, Winters GL, Fishbein MC, et al,. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
7. Costanzo MR, Dipchand A, Starling R, et al,. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914.
8. George JF, Pamboukian SV, Tallaj JA, et al,. Balancing rejection and infection with respect to age, race, and gender: clues acquired from 17 years of cardiac transplantation data. J Heart Lung Transplant 2010; 29: 966.
9. Subherwal S, Kobashigawa JA, Cogert G, Patel J, Espejo M, Oeser B,. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. Transplant Proc 2004; 36: 3171.
10. Kirklin JK, Naftel DC, Bourge RC, et al,. Rejection after cardiac transplantation. A time-related risk factor analysis. Circulation 1992; 86: S236.
11. Heimansohn DA, Robison RJ, Paris JM 3rd, Matheny RG, Bogdon J, Shaar CJ,. Routine surveillance endomyocardial biopsy: late rejection after heart transplantation. Ann Thorac Surg 1997; 64: 1231.
12. Spratt P, Sivathasan C, Macdonald P, Keogh A, Chang V,. Role of routine endomyocardial biopsy to monitor late rejection after heart transplantation. J Heart Lung Transplant 1991; 10: 912.
13. Zerbe T, Uretsky B, Kormos R, et al,. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant 1992; 11: 104.
14. Stoica SC, Cafferty F, Pauriah M, et al,. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006; 25: 420.
15. Raichlin E, Edwards BS, Kremers WK, et al,. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J Heart Lung Transplant 2009; 28: 320.
16. Jarcho J, Naftel DC, Shroyer TW, et al,. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. J Heart Lung Transplant 1994; 13: 583.
17. Aziz T, el-Gamel A, Krysiak P, et al,. Risk factors for early mortality, acute rejection, and factors affecting first-year survival after heart transplantation. Transplant Proc 1998; 30: 1912.
18. Prendergast TW, Furukawa S, Beyer AJ 3rd, Browne BJ, Eisen HJ, Jeevanandam V,. The role of gender in heart transplantation. Ann Thorac Surg 1998; 65: 88.
19. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE,. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
20. Decoene C, Pol A, Dewilde A, et al,. Relationship between CMV and graft rejection after heart transplantation. Transpl Int 1996; 9: 241.
21. Foerster A, Abdelnoor M, Geiran O, et al,. Morbidity risk factors in human cardiac transplantation. Histoincompatibility and protracted graft ischemia entail high risk of rejection and infection. Scand J Thorac Cardiovasc Surg 1992; 26: 169.
22. Carrier M, White M, Perrault LP, et al,. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 1999; 12: 1218.
23. Emin A, Rogers CA, Thekkudan J, Bonser RS, Banner NR,. Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study. J Heart Lung Transplant 2011; 7: 770.
24. Beniaminovitz A, Itescu S, Lietz K, et al,. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 9: 613.
25. Hershberger RE, Starling RC, Eisen HJ, et al,. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 26: 2705.
26. Barr ML, Sanchez JA, Seche LA, Schulman LL, Smith CR, Rose EA,. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation. Circulation 1990; 82: 291.
27. Adamson R, Obispo E, Dychter S, et al,. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience. Transplant Proc 1998; 4: 1107.
28. Almenar L, García-Palomar C, Martínez-Dolz L, et al,. Influence of induction therapy on rejection and survival in heart transplantation. Transplant Proc 2005; 9: 4024.
29. Cuppoletti A, Perez-Villa F, Vallejos I, Roig E,. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation. Transplant Proc 2005; 9: 4036.
30. Chin C, Pittson S, Luikart H, et al,. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 2005; 4: 477.
31. Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, et al,. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006; 11: 1542.
32. Carrier M, Leblanc MH, Perrault LP, et al,. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 2007; 3: 258.
33. Mattei MF, Redonnet M, Gandjbakhch I, et al,. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007; 7: 693.
34. Carlsen J, Johansen M, Boesgaard S, et al,. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant 2005; 3: 296.
35. Flaman F, Zieroth S, Rao V, Ross H, Delgado DH,. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 2006; 11: 1358.
36. Grimm M, Rinaldi M, Yonan NA, et al,. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 2006; 6: 1387.
37. Kobashigawa J, Miller L, Renlund D, et al,. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 4: 507.
38. Eisen HJ, Tuzcu EM, Dorent R, et al,. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 9: 847.
39. Keogh A, Richardson M, Ruygrok P, et al,. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 17: 2694.